Clinical Trials
39 trialsSAFIR-ABC10
UNICANCER
iNNOVATE
Virginia Commonwealth University
I-SPY
QuantumLeap Healthcare Collaborative
INTUITT-NF2
Massachusetts General Hospital
Neratinib + Valproate in Advanced Solid Tumors, w/Expansion Cohort in Ras-Mutated Ca
Virginia Commonwealth University
Capecitabine 7/7 Schedule With Neratinib in Patients With Metastatic HER2-Positive Breast Cancer
Memorial Sloan Kettering Cancer Center
Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers
Hoosier Cancer Research Network
Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer
M.D. Anderson Cancer Center
Neratinib In Combination With Chemotherapy/Trastuzumab/Pembrolizumab In HER2 Gastroesophageal Cancer
H. Lee Moffitt Cancer Center and Research Institute
HKI-272 for HER2-Positive Breast Cancer and Brain Metastases
Dana-Farber Cancer Institute
Neratinib +/- Fulvestrant in HER2+, ER+ Metastatic Breast Cancer
Dana-Farber Cancer Institute
GERTRUDE
Dartmouth-Hitchcock Medical Center
Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation
M.D. Anderson Cancer Center
Trial of Neratinib Plus Capecitabine in Subjects With HER2-Negative Metastatic Breast Cancer With Brain Metastases and Abnormally Active HER2 Signaling
University of Rochester
Safety and Dose Finding Study of Neratinib in Children and Young Adults With Cancer That Has Returned or Not Responded to Treatment
Memorial Sloan Kettering Cancer Center
INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)
Dana-Farber Cancer Institute
Neratinib in Combination With Ruxolitinib in Patients With mTNBC
Baylor Research Institute
Neratinib and Fam-Trastuzumab Deruxtecan in Advanced Gastro-esophageal Cancer Patients
Fox Chase Cancer Center
Adjuvant Trastuzumab Plus Neratinib in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer After Neoadjuvant Trastuzumab Plus Pertuzumab
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Neoadjuvant Neratinib in Stage I-III HER2-Mutated Lobular Breast Cancers
Vanderbilt-Ingram Cancer Center
THUNDER
Fudan University
Incidence and Severity of Diarrhea in Patients With HER2 Positive Breast Cancer Treated With Trastuzumab and Neratinib
University of California, San Francisco
Neratinib and Capmatinib Combination (Phase Ib/II) in Metastatic Breast Cancer and Inflammatory Breast Cancer Patients With Abnormal HER-family and c-Met Pathway Activity as Measured by the CELsignia Signaling Analysis Test
M.D. Anderson Cancer Center
DIANER
Spanish Breast Cancer Research Group
Neratinib and Trastuzumab Biosimilar in Patients with HER2 Mutated Advanced Solid Cancers
Korea University Guro Hospital
Using Tumor Models to Determine Treatments
University Health Network, Toronto
Kadcyla And Neratinib for Interception of HER2+ Breast Cancer With Molecular Residual Disease
University Health Network, Toronto
SPRING
Peking University Shenzhen Hospital
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
OHSU Knight Cancer Institute
FACT-2
West Cancer Center
HER2-Signal
Massachusetts General Hospital
Neratinib in Patients With Metastatic Castration-Resistant Prostate Cancer
Beth Israel Deaconess Medical Center
Neratinib in Treating Older Patients With Stage IV HER2-Positive Breast Cancer
City of Hope Medical Center
NEREA
SOLTI Breast Cancer Research Group
Neratinib +/- Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer
Washington University School of Medicine
NeraBrain
Jules Bordet Institute
TKIs vs. Pertuzumab in HER2+ Breast Cancer Patients With Active Brain Metastases (HER2BRAIN)
Second Affiliated Hospital, School of Medicine, Zhejiang University
plasmaMATCH
Institute of Cancer Research, United Kingdom
Phase1 of Neratinib+Trastuzumab, Pertuzumab, Paclitaxel in Patients With Advanced Solid Tumors/HER2+
University of California, San Francisco